EM1810F "Leveraging Genomics in Clinical Practice: Fulfilling the 'Promise' of Precision Medicine" (IM GR-101218)
To transform the clinical management of cancer in the near term, it is essential to develop drugs in more precisely defined and biologically relevant patient groups. The practice of precision medicine, where the choice of treatment is based on the biologic profile of an individual patient’s tumor, requires analytically valid assays for the integral biomarker(s) on which the selection of treatment will be made. However, for many treatments, the complexities of identifying a predictive biomarker, the complexities of developing analytically valid assays and the evidence needed to show clinical utility are grossly underestimated. To this end, numerous innovative, multidisciplinary trials and programs have been developed, and the concept of phenogenomics has been established, to best leverage genomics in clinical practice.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Appreciate the complex, multidisciplinary process for an assay to achieve analytical validation and ultimately regulatory approval.
- Know the difference between analytical and clinical validation
- Recognize advantage of “liquid biopsies” over conventional methods for obtaining genetic material
- Understand the relationship of phenotype to genotype as it applies to managing heterogeneous tumors
Howard I. Scher, M.D., FASCO
D. Wayne Calloway Chair in Urologic Oncology
Co-Chair, Center for Molecular Based Therapy
Head, Biomarker Development Initiative
Member and Attending Physician Genitourinary Oncology Service,
Department of Medicine, Memorial Sloan Kettering Cancer Center
Pamala Hearn Isom Visiting Professorship in honor Eugene P. Frenkel, M.D.
- 1.00 AMA